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Abstract 
BACKGROUND: Systemic inflammation in bronchiectasis is poorly studied in relation to 
aetiology and severity. We hypothesized that molecular patterns of inflammation may 
define particular aetiology and severity groups in bronchiectasis. 
METHOD: We assayed blood concentrations of 31 proteins from 90 bronchiectasis patients 
(derivation cohort) and conducted PCA to examine relationships between these markers, 
disease aetiology and severity.  Key results were validated in two separate cohorts of 97 and 
79 patients from other centres. 
RESULTS: There was significant heterogeneity in protein concentrations across the 
derivation population.  Increasing severity of bronchiectasis (BSI) was associated with 
increasing fibrinogen (rho= 0.34, p=0.001 –validated in a second cohort), and higher 
fibrinogen was associated with worse lung function, Pseudomonas colonisation and 
impaired health-status.  There were generally similar patterns of inflammation in patients 
with idiopathic and post-infectious disease.  However, patients with primary 
immunodeficiency had exaggerated IL-17 responses, validated in a second cohort (n=79, 
immunodeficient 12.82pg/ml versus idiopathic/post-infectious 4.95pg/ml, p=0.001), and 
thus IL-17 discriminated primary immunodeficiency from other aetiologies (AUC 0.769 
(95%CI 0.661-0.877)). 
CONCLUSION: Bronchiectasis is associated with heterogeneity of systemic inflammatory 
proteins not adequately explained by differences in disease aetiology or severity.  More 
severe disease is associated with enhanced acute-phase responses.  Plasma fibrinogen was 
associated with bronchiectasis severity in two cohorts, Pseudomonas colonisation and 
health status, and offers potential as a useful biomarker. 
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Introduction 
Bronchiectasis is a neglected chronic inflammatory airway condition that is the end 
anatomical result of diverse aetiological insults.  Whilst it has been known for some time 
that bronchiectasis is also associated with systemic inflammation [1], the nature of this 
response has not been well studied in relation to bronchiectasis aetiology and severity.  
Importantly, no previous studies have examined whether inflammation differs between 
major causes of bronchiectasis such as idiopathic and post-infectious disease.  Indeed, there 
are no existing data examining a comprehensive panel of inflammatory proteins in the 
systemic compartment of patients with bronchiectasis. 
 
Current concepts of bronchiectasis severity emphasise the importance of multi-component 
assessment [2, 3].  Scores such as the Bronchiectasis Severity Index (BSI) [2] and FACED [3] 
have been applied to either predict mortality and/or morbidity such as, hospital admissions, 
exacerbation frequency and quality of life.  There is also a paucity of data examining causes 
of death in bronchiectasis despite a suggestion of increased cardiovascular risk [4].  This is a 
concept well established in other chronic airway diseases such as chronic obstructive 
pulmonary disease (COPD) and which may relate to systemic inflammation [5].  There is 
therefore the need to examine how bronchiectasis severity is associated with systemic 
inflammation and, in particular, which components of bronchiectasis severity drive this 
association. 
 
We designed a study to address the hypotheses that systemic inflammatory markers can 
distinguish aetiology and severity groups in bronchiectasis, employing an unsupervised 
principal component analysis. In doing so we have conducted the largest and most 
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comprehensive analysis of systemic inflammatory proteins in bronchiectasis ever reported.  
Moreover, we validated key results in two replication cohorts.  Our results inform on the 
heterogeneity of systemic inflammatory responses in bronchiectasis with regard to 
aetiology and severity of disease. 
 
 
Method 
90 patients with stable, clinically significant bronchiectasis – defined as regular sputum 
production and/or recurrent respiratory infections with a diagnostic computed tomography 
(CT) scan - were recruited as a convenience sample from out-patient clinics at the Royal Free 
London and University College London Hospitals NHS Foundation Trusts, UK. Patients with a 
primary clinical diagnosis of COPD were excluded.  These patients formed the derivation 
cohort.  Patients were only recruited if free from exacerbation treated with antibiotics for 
one month or more.  Patients provided written informed consent, and the study was 
approved by Hampstead Research Ethics Committee (10/H0720/43). 
 
1.  Clinical Assessment 
For the purposes of this analysis, information was collated to permit allocation of patients 
into aetiological groups according to the British Thoracic Society guideline [6].  Idiopathic 
disease was defined as the absence of an alternative more plausible cause of bronchiectasis. 
 
Bronchiectasis severity was first assessed using the Bronchiectasis Severity Index [2] and 
therefore data on age, body mass index (BMI), most recent lung function (forced expiratory 
volume in 1 second, FEV1), self-reported hospitalisation (previous two years) and 
4 
 
exacerbations (previous year), Medical Research Council (MRC) dyspnoea scale, the 
presence of colonising organisms on routine sputum culture and radiological extent of 
disease on the most recent CT scan were collated and entered into the online BSI calculation 
tool: http://www.bronchiectasisseverity.com/.  Mild bronchiectasis was defined as a score 
of 0-4, moderate as 5-8 and severe as ≥9 units.  To provide further information in relation to 
bronchiectasis severity, we also calculated the alternative FACED bronchiectasis mortality 
score [3], which includes age, FEV1, lobar involvement, dyspnoea (mMRC score) and 
Pseudomonas colonisation status.  The FACED score is as follows: mild 0–2 points, moderate 
3–4 points and severe 5–7 points. 
 
2.  Assessment of Serum Proteins 
Venous blood samples were drawn.  A citrated plasma sample was analysed for fibrinogen 
using the Clauss method (IL ACL Top Coagulation Analyzer; Instrumentation Laboratories, 
Lexington, MA).  A serum sample was analysed for C-Reactive Protein using a Modular 
Analytics E 170 Module (Roche, Burgess Hill, UK).  A second serum sample was centrifuged 
(10 minutes, 2000rpm, 4OC) with the supernatant then stored at -80OC for later analysis of 
the remaining 29 mediators (see Table 1).  These were assessed using the Meso Scale 
Discovery Platform ‘V-PLEX Human Cytokine 30-Plex Kit’ (Meso Scale Discovery, Rockville, 
MD, US) according to the manufacturer’s instructions. 
 
3.  Validation Cohorts 
Key results were validated in two samples of patients from specialist bronchiectasis clinics in 
Dundee and Newcastle, UK.  These patients had clinically significant bronchiectasis and also 
underwent standardised testing according to BTS recommendations, as in the derivation 
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cohort.  Ethical approval was granted (12/ES/0059 and 12/NE/0248 respectively).  
Fibrinogen was measured by the Clauss method (Dundee patients).  Serum IL-17 (Newcastle 
patients) was measured using a commercial quantitative enzyme-linked immunosorbent 
assay (ELISA) kit, according to the manufacturer’s protocol (DuoSet® ELISA Development 
System, human IL-17, R&D Systems, UK).  Health status as assessed by the St. George’s 
Respiratory Questionnaire (SGRQ) was available in the Dundee patients. 
 
4.  Statistical Analysis 
Statistical analysis was performed in IBM SPSS version 22 (IBM Corporation, Armonk, NY, 
US).  Data were tested for normality using the Kolmogorov-Smirnov test.  Clinical data are 
reported as mean and standard deviation (SD) or median and interquartile range (IQR) as 
appropriate. 
 
The majority of the serum proteins were not normally distributed and therefore all were 
log10 transformed for further analysis.  As described in Table 1, any assays below the 
detection limit were assigned a value of half that lower limit of detection (LLD).  17 missing 
fibrinogen results in the derivation cohort arising because no plasma sample was available 
were single-imputed based on a significant correlation between fibrinogen and CRP 
(rho=0.572, p<0.001).  We validated a key finding in relation to fibrinogen using minimum, 
mean and maximum values derived from multiple imputation using the ‘mi’ command in 
STATA version 14 (www.stata.com). 
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We used Principal Component Analysis (PCA) [7] to assess variation in the proteins across 
the population.  The protein most closely correlated with each of the first five principal 
components was selected as a key exemplar protein for that principal component. 
 
Radar plots [8] were employed to illustrate the concentrations of these five key proteins 
across disease severity and aetiology.  To do this, the concentration of each of these 
proteins was expressed as the quartile of the concentration it was contained in, derived 
from the concentrations across all 90 patients.  The mean of each of these quartile values 
was then used to construct the radar plot. 
 
Correlations were assessed using Pearson or Spearman Rank as appropriate, and differences 
between medians tested by Mann-Whitney U analysis for two groups, and Kruskal–Wallis 
one-way analysis of variance when more than two groups were tested.  We also employed 
multiple linear regression and receiver-operating characteristic (ROC) analysis. 
 
A p value <0.05 was considered statistically significant. 
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Results 
The 90 patients (57, 63% women) in the derivation cohort had a median (IQR) age of 61 (46-
71) years, BSI score of 5 (3-8) units and FACED score of 2 (1-3) units.  Within the variables 
contributing to the BSI, the mean (SD) FEV1 was 72.4 (27.5) % predicted, and exacerbation 
frequency 2 (1-3) events/year.  The three largest aetiological groups were post-infection (18 
patients), idiopathic (20 patients) and primary immunodeficiency (25 patients, all of whom 
had CVID) which together accounted for 70% of the cohort in total.  A sputum culture result 
within six months of the sampling visit was available in 30/90 patients.  Patients were 
additionally asked if they recalled a positive sputum culture over the previous year where 
samples had been sent to referring hospitals.  Regarding therapy, 37 patients were 
prescribed an inhaled corticosteroid, 18 a long-term macrolide, 19 a long-term antibiotic 
other than a macrolide, eight were prescribed long-term oral corticosteroids and seven 
long-term immunosuppression other than corticosteroids.  The results of analysis of the 31 
systemic proteins are reported in Table 1. 
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TABLE 1: Results of the analysis of 31 proteins in 90 patients with bronchiectasis from the derivation 
cohort.  All results are expressed as geometric mean (SD) pg/ml except Fibrinogen (g/l) and CRP 
(mg/l). 
(all logs) 
 
n= above the lower limit of detection Mean (SD) 
   
CRP 90 2.8 (3.9) 
Eotaxin 90 147.9 (1.9) 
Eotaxin-3 73 14.1 (3.3) 
Fibrinogen 90 3.5 (1.4) 
GM-CSF 83 0.4 (2.3) 
IFN-γ 84 9.1 (3.4) 
IL-1α 41 0.4 (6.2) 
IL-1β 53 0.1 (4.3) 
IL-2 45 0.3 (4.3) 
IL-4 37 0.1 (3.4) 
IL-5 86 0.5 (2.6) 
IL-6 86 1.3 (2.5) 
IL-7 90 15.1 (1.6) 
IL-8 90 13.5 (2.8) 
IL-10 78 0.4 (3.2) 
IL-12p40 90 107.2 (2.2) 
IL-12p70 65 0.7 (2.3) 
IL-13 63 6.9 (1.7) 
IL-15 90 2.3 (1.4) 
IL-16 90 257.0 (1.6) 
IL-17 90 4.0 (2.6) 
IP-10 90 309.0 (2.5) 
MCP-1 90 263.0 (1.8) 
MCP-4 90 81.3 (1.6) 
MDC 90 831.8 (1.7) 
MIP-1α 83 21.9 (1.6) 
MIP-1β 90 112.2 (1.6) 
TARC 90 275.4 (2.1) 
TNF-α 90 1.8 (1.6) 
TNF-β 79 0.2 (2.8) 
VEGF 90 109.6 (1.9) 
Values below the lower limit of detection were assigned a value of half that lower limit. 
 
1.  Principal Component Analysis 
Great heterogeneity was observed in the analysis of systemic protein markers across the 
dataset.  An unsupervised principal component analysis met the criteria for data adequacy 
(Bartlett’s test of Sphericity and Kaiser-Meyer-Olkin measure of sample adequacy) and 
yielded 10 factors with an Eigen value>1.  Monte-Carlo parallel analysis based on a 
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theoretical population of 100 subjects suggested a five factor solution, which then explained 
only 52% of the variance.  Table 2 presents the five extracted factors, and the two serum 
proteins most closely associated with those factors.  Principal component 1, the component 
associated with the greatest variance across the derivation cohort, was most closely 
correlated with Monocyte Chemoattractant Protein (MCP)-1. 
 
TABLE 2: Principal Component analysis of 31 proteins in the blood of 90 patients with bronchiectasis 
in the derivation cohort identified five components that explained 52% of variance.  The number in 
brackets represents the strength of the association between that marker and the respective principal 
component. 
Component Nature Correlates 
1 ‘Mononuclear Chemotaxis’ MCP-1 (0.841); MDC (0.773) 
2 ‘Immune Regulation’ IL-13 (-0.759); IL-12p70 (-0.729) 
3 ‘Acute Phase Response’ Fibrinogen (0.719); CRP (0.711) 
4 ‘Immune Activation’ IL-17 (0.796); IL-12p40 (0.596) 
5 ‘Polymorphonuclear Chemotaxis’ IL-8 (0.638); IL-16 (0.633) 
 
We next went on to explore differences by disease severity (BSI and FACED score) and 
aetiology in patterns of these components, using the first key cytokine associated with that 
component. 
 
2.  Bronchiectasis Severity and Systemic Inflammatory Proteins 
Figure 1A presents a Radar Plot of the five key systemic inflammatory proteins (representing 
each of the Principal Components) by bronchiectasis severity (BSI score) in the derivation 
cohort.  To mitigate heterogeneity due to aetiology, Figure 1B presents data solely from the 
18 patients with post-infectious disease (likely to be the most homogeneous group). 
 
In both the total derivation cohort and the selected patients with post-infectious aetiology, 
there was a step-wise increase in fibrinogen from mild through moderate to severe patients, 
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but significant heterogeneity in the other four markers.  Reflecting this, in the whole 
derivation cohort, we observed a significant correlation between the plasma fibrinogen 
concentration and BSI score (rho=0.34, p=0.001, Figure 2A).  This was robust to analysis 
using minimum, mean and maximum fibrinogen values derived from multiple rather than 
single (CRP-based) imputation (r=0.23 p=0.03; r=0.37 p<0.001 and r=0.41 p<0.001 
respectively).  A similar relationship was present between mortality risk assessed by the 
FACED score and plasma fibrinogen concentration (rho=0.27, p=0.014, Figure 2B).  There 
were no significant correlations between BSI score and the other four markers. 
 
We sought to validate the relationship between BSI and plasma fibrinogen by replicating 
this finding in a separate cohort.  Fibrinogen concentration was available in 97 patients from 
Dundee, UK.  These patients had a median (IQR) age 65 (58-72) years and FEV1 1.72 (1.11-
2.48)l, 50% were female and the two commonest aetiologies were idiopathic (46%) and 
post-infectious (19%) disease.  Only three patients in this cohort had primary 
immunodeficiency.  The median (IQR) BSI was 7 (4-12) and fibrinogen 3.6 (2.7-4.8) g/l.  
There was a significant relationship between BSI and fibrinogen in this second independent 
group of patients (rho= 0.36, p<0.001), of strikingly similar strength to that in the derivation 
cohort thus demonstrating the finding to be robust.  There was also a significant 
relationship between plasma fibrinogen and the St. George’s Respiratory Questionnaire 
(rho=0.25, p=0.013), indicating that fibrinogen also reflects health-status in bronchiectasis. 
 
Finally, we examined which components of the BSI score were most closely associated with 
the plasma fibrinogen concentration by conducting a multi-variable analysis with fibrinogen 
as the dependent variable and each of the BSI components included as predictors (using the 
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allocated BSI ‘points’ rather than raw values [2]).  This was conducted in the combined UCL 
and Dundee cohorts of 187 patients.  The overall model fit (R2)=0.17, and the variables 
significantly associated with (higher) plasma fibrinogen were (greater) age (β=0.201; 
p=0.006), (lower) FEV1 (β=0.178; p=0.030) and (the presence of) Pseudomonas aeruginosa 
colonisation (β=0.170; p=0.039).  20 of the 187 patients (10.7%) in the combined cohort 
were P.aeruginosa colonised. 
 
 
3.  Bronchiectasis Aetiology and Systemic Inflammatory Proteins 
Figure 3A represents a Radar Plot of the five key systemic inflammatory proteins 
(representing each of the Principal Components) by the three commonest bronchiectasis 
aetiologies in the whole derivation cohort.  To mitigate heterogeneity due to severity, Figure 
3B presents data solely from the 25 patients with moderate disease (BSI score 5-8). 
 
Whilst the profiles of the post-infectious and idiopathic patients look similar, patients with 
primary immunodeficiency appear to have up-regulated IL-17 responses.  Reflecting this, the 
median log10 serum IL-17 concentration was significantly different across the three groups 
(idiopathic / post-infectious / primary immunodeficiency 0.45 vs. 0.45 vs. 0.82 log10 pg/ml, 
p<0.001), but there were no significant differences for the other four markers by 
bronchiectasis aetiology (MCP p=0.439, IL-13 p=0.223, Fibrinogen p=0.138 and IL-8 
p=0.549). 
 
Next, we went on to test the principle that IL-17, as an exemplar serum protein, might be of 
practical use in the diagnosis of bronchiectasis aetiology.  Figure 4 presents a Receiver 
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Operating Characteristic (ROC) curve for the ability of IL-17 to distinguish primary 
immunodeficiency from idiopathic and post-infectious aetiology.  The area under the curve 
((AUC)=0.769 (95%CI 0.661-0.877, p<0.001)) approaches the standard 0.8 cut off for utility, 
which falls within the 95%CI.  Reporting geometric means, a serum IL-17 concentration of 
3.23pg/ml would be 90% sensitive and 63% specific, and a concentration of 6.46pg/ml 
would be 90% specific and 50% sensitive for the identification of bronchiectasis associated 
with primary immunodeficiency.  We have not reported positive and negative predictive 
values as these are dependent on prevalence. 
 
We next sought to validate the difference in serum IL-17 between primary 
immunodeficiency versus idiopathic and post-infectious disease by replicating this finding in 
a separate cohort.  Serum IL-17 concentration data were available in 79 patients from 
Newcastle, UK.  These patients had a median (IQR) age 64 (61-70) years, FEV1 1.59 (1.07-
2.06) l, and 65% were female.  50 patients had post-infectious disease, 19 had idiopathic 
disease and 10 patients had bronchiectasis associated with primary immunodeficiency.  The 
median (IQR) serum IL-17 was 5.37 (2.43-12.19)pg/ml.  There was a significant difference in 
serum IL-17 concentration between patients with primary immunodeficiency versus those 
with idiopathic/post-infectious disease (12.82 vs. 4.95pg/ml, p=0.001 respectively), thus 
demonstrating the derivation cohort finding to be robust. 
 
Finally, as were specifically interested in differences in protein expression in patients with 
idiopathic versus post-infectious disease, we compared the median values of the remaining 
26 markers across these two groups in the derivation cohort.  The only significant difference 
was for IL-4, which was higher in the post-infectious than the idiopathic group (p=0.025), 
13 
 
but IL-4 was detectable in only 37 of 90 patients (Table 1).  A chi square analysis examining 
detectable versus non-detectable IL-4 concentration by post-infectious versus idiopathic 
disease did not reach statistical significance (detectable 11/18 vs. 6/20 p=0.101).  The AUC 
(95%CI) for the ROC of IL-4 to differentiate these two aetiologies was 0.694 (0.521-0.868), 
p=0.041. 
 
 
Discussion 
We present the most comprehensive analysis of systemic immune and inflammatory 
proteins from patients with bronchiectasis ever reported.  Our findings may be summarised 
thus: first, there is significant heterogeneity in systemic proteins between patients which is 
not fully accounted for by differences in either bronchiectasis aetiology, or bronchiectasis 
severity.  Second, a global assessment of bronchiectasis severity (and health status) is 
associated with an increasing systemic acute-phase response.  Third, we demonstrate the 
important principle that profiles of serum inflammatory proteins may differ significantly 
between aetiology subgroups, but we were unable to demonstrate significant differences in 
patterns of proteins between idiopathic and post-infectious disease. 
 
The classic vicious cycle hypothesis of Cole [9] presents (airway) inflammation as a key 
component of bronchiectasis.  It has been known for some time that patients with 
bronchiectasis also present a systemic inflammatory response [1] including up-regulated 
expression of circulating leukocyte adhesion molecules [10] even when clinically stable.  The 
former analysis of differential leukocyte count, CRP, erythrocyte sedimentation rate and 
serum immunoglobulins in 87 patients reported significant associations between systemic 
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inflammation and bronchiectasis severity as assessed both by CT scan and lung function.  It 
was subsequently shown that systemic inflammation is elevated in patients with high airway 
bacterial load, and that this effect can be modified with antibiotic therapy [11].  We now 
recognise bronchiectasis as a complex disease which is best assessed using multi-
component scores [2, 3].  However, there are no existing studies examining a 
comprehensive panel of systemic protein markers in patients with bronchiectasis, allowing 
an assessment of protein heterogeneity by severity and aetiology. 
 
We first took an unsupervised principal component analysis of 31 candidate proteins 
representing a wide range of immune and inflammatory mechanisms and identified five 
components accounting for 52% of the variance.  In broad terms, these components 
represented proteins involved in chemotaxis of mononuclear and polymorphonuclear 
leukocytes, proteins associated with immune regulation, immune activation, and 
components of the acute-phase response.  To avoid problems resulting from a multiplicity of 
statistical tests, we went on to conduct further analysis only in the single protein most 
closely associated with each of the five principal components. 
 
The finding that a five component PCA accounted for only around half of the total variance 
demonstrates the degree of heterogeneity in systemic protein responses.  Most of the 
variance was seen in markers of mononuclear chemotaxis, exemplified by MCP-1, yet this 
variance was not explained by differences in either the aetiology or severity of disease.  
MCP-1 (CCL2) is a CC chemokine responsible for recruiting monocytes, T-lymphocytes and 
dendritic cells to sites of inflammation [12].  A role for MCP-1 has not previously been 
reported in bronchiectasis.  Further work is required to explore the factors determining the 
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variance in this marker between patients, and its potential as an outcome marker or 
therapeutic target.  Whilst bronchiectasis is usually considered a condition of principally 
neutrophilic inflammation, variance in serum IL-8 concentration was also unexplained by 
differences in bronchiectasis aetiology and severity.  This is perhaps not surprising as 
recruitment and activation of neutrophils occurs locally in the airway and not in the 
systemic circulation.  
 
With the possible exception of IL-4, we were unable to define differences in systemic 
protein responses between individuals with idiopathic and post-infectious bronchiectasis, 
the two commonest causes in clinical practice in the developed world.  Further study of IL-4 
in this context is warranted.  However, differentiating between idiopathic and post-
infectious bronchiectasis is challenging because patients classified as idiopathic may have 
had unreported respiratory infection, and where bronchiectasis is classified as post-
infectious there may be recall bias with tenuous linkage to a previous, often childhood, 
infection.  Anwar et al [13] suggested that post-infectious bronchiectasis may be a valid 
subgroup as patients had an earlier onset of disease, but evidence to date as to whether 
idiopathic and post-infectious disease are separate phenotypes remains inconclusive.  Our 
data demonstrate that these aetiologies are difficult to differentiate in terms of systemic 
inflammatory profiles. 
 
Our finding of greater IL-17 responses in patients with primary immunodeficiency was 
validated in an independent cohort. This raises the possibility that assessment of serum 
proteins may have utility in the differential diagnosis of bronchiectasis although prospective 
analysis would be required to confirm such a hypothesis.  IL-17 has a key role in inducing 
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and mediating pro-inflammatory responses [14].  IL-17 is produced by a variety of immune 
cells, classically though not solely T-helper 17 cells, and acts on epithelial cell, endothelium 
and fibroblasts to result in release of pro-inflammatory mediators including IL-8, and drives 
neutrophil recruitment.  Elevated airway IL-17 has been previously reported in patients with 
bronchiectasis [15]. In asthma, systemic IL-17 is elevated and airway IL-17 has been 
associated with more severe and neutrophilic asthma phenotypes [16, 17] while elevated 
airway IL-17 in COPD has been associated with lower FEV1/FEV ratio [18].  That 
bronchiectasis in immunodeficiency may be associated with exaggerated as well as deficient 
responses is consistent with our earlier work defining greater airway inflammation and 
systemic CRP in bronchiectasis associated with primary antibody deficiency syndromes 
compared to immuno-competent bronchiectasis subjects [19].  Further work comparing 
systemic IL-17 between primary antibody deficient patients with and without bronchiectasis 
would help to evaluate a possible role of this pro-inflammatory cytokine in the development 
of bronchiectasis.  Identification of IL-17 pathways is important as monoclonal drugs are 
available to target IL-17 and, indeed, macrolide antibiotics (which are effective at reducing 
exacerbations in bronchiectasis [20-22]) have been shown to reduce IL-17 expression in 
patients with bronchiectasis [23]. 
 
Global assessments of bronchiectasis severity were associated with an increasing acute-
phase response, exemplified by plasma fibrinogen concentration, and we replicated this 
result in an independent cohort.  This effect was driven largely by the reduction in lung 
function, P. aeruginosa colonisation and age.  Our findings are in keeping with Wilson’s 1998 
report of an association between lung function and systemic inflammation in bronchiectasis 
[1].  Systemic inflammation may provide the link between airway inflammatory diseases and 
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the increased cardiovascular risk observed in such conditions [5], of clinical importance 
because many patients with COPD, for example, die from co-morbid cardiovascular disease 
[24].  As a coagulation protein, fibrinogen may be directly involved in cardiovascular risk.  
The concept of cardiovascular risk in bronchiectasis is poorly studied, but we have recently 
reported that patients with bronchiectasis are at increased risk of cardiovascular events 
compared to a control population [4].  Our results raise the hypothesis that preservation of 
lung function and, perhaps, prevention of P. aeruginosa colonisation could be important 
strategies to mitigate the excess cardiovascular risk associated with bronchiectasis.  The 
utility of biomarkers such as fibrinogen in adding to mortality prediction in COPD [25] has 
resulted in FDA consideration of this protein as a surrogate outcome measure in clinical 
trials in COPD [26].  There is therefore the need to understand further the role of fibrinogen 
in bronchiectasis.  Levels of fibrinogen identified in severe bronchiectasis were consistent 
with levels identified in frequently exacerbating COPD suggesting an important systemic 
inflammatory component to both independent conditions [27]. 
 
A major strength of our study is that we have validated our two key findings in independent 
cohorts.  However a limitation, common to all bronchiectasis studies, is that populations 
vary across centres depending on local referral patterns.  In our derivation population, for 
example, we were not able to explore systemic protein responses in bronchiectasis 
associated with other immune-dysregulated conditions such as rheumatoid arthritis.  Whilst 
patients with idiopathic and post-infectious disease represent a sizeable proportion of the 
derivation cohort as one would expect in the UK, our clinical practice includes a tertiary 
immunology service and therefore patients with primary immunodeficiency are over-
represented in the derivation cohort.  For this reason, we have reported the sensitivity and 
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specificity of IL-17 cut-points for diagnosing immunodeficiency-associated bronchiectasis, 
rather than positive and negative predictive values which depend on prevalence.  Cost 
constraints would prohibit comprehensive unsupervised analysis in very large populations 
and therefore our principal component analysis provides useful data on which systemic 
proteins in bronchiectasis are responsible for most of the inter-patient variation, with the 
novel identification of MCP-1.  A further potential use for systemic proteins is to assess 
disease progression, but this would require longitudinal rather than cross-sectional 
analyses.  We were not able to study relationships between airway bacterial density or the 
microbiome and systemic proteins, a limitation of our work and this would be an important 
area for future research.  All samples were taken from patients at least one month following 
a preceding exacerbation; it is possible that in some patients’ inflammatory responses may 
not have fully resolved.  Greater periods of stability prior to sampling may arguably give a 
more  accurate baseline. This however may lead inadvertently to bias by excluding those 
with more severe bronchiectasis and higher exacerbation frequencies from being studied. 
Furthermore, the range of anti-inflammatory and anti-infective medications used in our 
cohort prevent us from commenting on the effect of individual or combination therapies on 
systemic protein concentrations, which would therefore also be a further important area of 
future study. 
 
In summary, we report significant heterogeneity in systemic inflammation between patients 
with bronchiectasis.  This heterogeneity is not solely associated with either disease aetiology 
or severity.  Indeed, the profiles of inflammation were generally similar in heterogeneity 
across the two most important aetiologies: idiopathic and post-infectious disease.  A global 
index of bronchiectasis severity was associated with an increased acute-phase response, in 
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two cohorts.  This finding offers insight into a possible role for fibrinogen and increased 
cardiovascular risk in bronchiectasis.  We also provide proof-of-principle that assessment of 
systemic proteins may support diagnosis of rarer, specific causes of bronchiectasis.   
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Figure Legends 
 
FIGURE 1: Radar plots of five serum inflammatory proteins by severity of bronchiectasis in 
the whole derivation cohort (Figure 1A) and only those patients with post-infectious disease 
(Figure 1B).  The green line represents mild disease (BSI score 0-4), orange line moderate 
disease (BSI score 5-8) and black line severe disease (BSI >9 units).  Numbers refer to 
quartiles of (log10) serum concentration. 
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FIGURE 2: BSI Bronchiectasis Score (Figure 2A) and FACED Score (Figure 2B) correlate with 
serum fibrinogen concentration in the derivation cohort (rho= 0.34, p=0.001 and rho= 0.27, 
p=0.014 respectively). 
2A: 
 
2B: 
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FIGURE 3: Radar plots of five serum inflammatory proteins by the three most common 
aetiologies of bronchiectasis in the whole derivation cohort (Figure 3A) and only those 
patients with moderate disease (Figure 3B).  The blue line represents idiopathic patients, the 
purple line post-infectious patients and the black line patients with primary 
immunodeficiency.  Numbers refer to quartiles of (log10) serum concentration. 
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FIGURE 4: Receiver Operating Characteristic (ROC) curve for the ability of serum IL-17 
concentration to differentiate primary immunodeficiency from other causes of bronchiectasis 
in the derivation cohort (AUC= 0.769 (95%CI) 0.661-0.877 p<0.001). 
 
 
 
 
 
